Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLS-5300 (INO-4700) Phase I/IIa MERS-CoV Vaccine Study
NCT03721718Phase 2Completed
- Sponsor
- GeneOne Life Science, Inc.
- Start
- Aug 2018
- Primary completion
- May 2019
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of INO-4700 in Middle East respiratory syndrome (MERS), sponsored by GeneOne Life Science, Inc.. Started Aug 2018; status: completed.
02
Drugs
INO-4700
03
Conditions
Middle East respiratory syndrome (MERS)
Beyond the preview
Go deeper on NCT03721718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03721718.